Grants for Small businesses - Federal

The FY24 Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer. The transformation intended by the consortium must be in peoples lives, and not in the healthcare or research system.This funding opportunity is a separate mechanism from the Transformative Breast Cancer Consortium Development Award, which is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). For FY24, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. It is not necessary to receive a development award in order to apply for the current funding opportunity or anticipated full consortium awards in the future. Detailed information on the FY24 Transformative Breast Cancer Consortium Development Award is available under a separate program announcement (HT942524BCRPTBCCDA).For the FY24 Transformative Breast Cancer Consortium Award, the consortium should have at least four, but no more than five, project teams, each investigating different projects under a central hypothesis. No more than two project teams may be based at one institution. Each teams work must be integrated within the consortium so that every component is working toward the consortiums central hypothesis. Note: This award is not intended to replace, supplement, duplicate, or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPOREs), and it should not represent a collection of related Program Project grants or subprojects.The proposed consortiums overall work is expected to be innovative. In addition, the Transformative Breast Cancer Consortium Award will include funds for seed projects to pursue brand-new, high-risk/high-reward concepts that arise from the work, during the award period.DOD FY24 Transformative Breast Cancer Consortium Award 5The Breast Cancer Landscape describes the reality of breast cancer and identifies overarching challenges to progress the field. Research funded under this award mechanism should result in answers that will fundamentally and significantly transform and disrupt the present landscape.Applications submitted to the Transformative Breast Cancer Consortium Award must include the following: Research that includes truly innovative and brand-new, paradigm-shifting work in breast cancer that will address vital issues in a unique way. The issues may be one (or more) of the FY24 BCRP Overarching Challenges or, with justification, may be a different issue that meets the intent of the award mechanism and addresses the mission of ending breast cancer. If the application identifies a different fundamental issue, it must be coupled with at least one of the FY24 BCRP Overarching Challenges. Research that includes different disciplines that come together to address ending breast cancer with an ecologic approach. The consortiums proposed research must look at all aspects of the disease and bring together these different perspectives into one overarching plan for a deep, definitive dive into the FY24 BCRP Overarching Challenge(s) or other fundamental issue identified in the application. The plan also should include issues related to the hypothesis that have not been previously addressed or answered. A plan that describes in detail the integration across the consortium in all aspects, including administration, logistics, and substance. Applications must describe the substantive integration across and among teams that are necessary for the work. The required communication plan and administrative management plan will not suffice to show integration, nor will identifying individual team members who will cross teams. A detailed explanation of the substantive research processes that will be integrated is required.Synergistic, highly integrated, multidisciplinary, and multi-institutional research teams of leading scientists, clinicians, and consumer advocates must be assembled into a consortium to address a major problem in a way that could not be accomplished by a single investigator or group. While the project teams are made up of different groups, each with its own Principal Investigator (PI), the teams must be working on the major problem identified in the Transformative Breast Cancer Consortium Award application and under the leadership of the Consortium Director. The research proposed in Transformative Breast Cancer Consortium Award applications may include phase 1 clinical trials and collaborations with pharmaceutical or biotechnology industry scientists and/or companies, as appropriate. However, a clinical trial is not required, and the primary thrust of the application should not be a clinical trial.Although not all-inclusive, applications that propose the following as the primary effort(s) or central hypothesis of the consortium will not meet the intent of this award mechanism: NCI Program Project or SPORE grants or applications Conducting drug screens or testing a cocktail of therapeutics Targeting a single gene or protein Developing a new derivative or formulation of an old drug Conducting genomic landscape mapping analyses Seeking to improve existing technologies (e.g., mammography or magnetic resonance imaging screening)All applications submitted to the Transformative Breast Cancer Consortium Award must address the following key features:1. IMPACTDemonstrate potential to transform or improve the lives of individuals with, and/or at risk for, breast cancer. The time to the final impact may vary, but the outcomes of the effort must be transformative and significantly advance the BCRPs mission of ending breast cancer. A clear and compelling presentation of how the effort will be transformative for individuals with, and/or at risk for, breast cancer must be provided. Applications proposing research that represents an incremental advance in breast cancer do not meet the intent of this award mechanism.2. INNOVATIONPursue innovative, high-risk/high-reward research that has the potential to change existing paradigms, or develop new paradigms. Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. In addition to the requirement that the consortiums overall research be innovative, applications must describe a plan to support the pursuit of innovative concepts through seed projects, i.e., the development of new concepts that emerge during the course of the award. These seed projects should enable the research team to explore new avenues of high-risk/high-reward ideas that were not part of the original application, but that develop during the project and are within the scope of the overall vision of the research. A portion of the total direct budget costs (no more than 5%) must be reserved to support the seed projects, and these funds may not be used for equipment or travel.3. CONSORTIUMIntegrate project teams consisting of preeminent investigators and advocates from appropriate disciplines and institutions. Applications should include a robust consortium of researchers with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the proposed research. Emphasis must be placed on integrating the most highly qualified investigators and advocates to focus on the research problem, regardless of their location. These investigators must include highly accomplished scientists, clinicians, and promising young investigators in the targeted areas of research who collectively represent the best team to solve the problem(s) identified. The proposed research effort should be broad enough to require a multidisciplinary approach that is reflected in the composition of the consortium team. Inclusion of scientists from nontraditional disciplines is encouraged.The award mechanism is structured with a Consortium Director and at least three, but no more than four, Project Team PIs representing at least two institutions. The Consortium Director is responsible for the day-to-day management of the consortium, as well as for leading their own project team. The Consortium Director, together with the Project Team PIs, are jointly responsible for leading and executing the proposed research projects that are integrated into a central hypothesis and will result in answers that will fundamentally and significantly transform and disrupt the present breast cancer landscape. Please see the top of this section, Section II.B, Award Information, for more details.Incorporate breast cancer consumer advocates into every aspect of the proposed consortiums activities. Applications are required to include consumer advocate involvement. The consortium team must include at least one breast cancer consumer advocate per project team. The consumer advocates are expected to represent the perspective of the patient population(s) that are most relevant to the consortiums proposed research. Breast cancer consumer advocates must have an active role in every aspect of the proposed consortiums work including consortium conception and design, ongoing discussion, decisions and oversight, program evaluation, and dissemination of information to the public. Consumer advocates must be integrated into and play an active role in the leadership and decision-making committees for the consortium at each participating institution. Examples of appropriate integration include membership on the advisory board(s) and steering committee(s), participation in each project team, and attendance at all consortium-related meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, they should be part of a breast cancer advocacy organization, and their role in the project should be independent of their employment. They cannot be employees of any of the institutions participating in the application. They must have a high level of familiarity and training involving science and current issues in breast cancer research.4. INTEGRATIONProvide a plan that describes in detail the integration across the consortium in all aspects, including administration, logistics, and substance. Applications must demonstrate the substantive integration across and among teams that are necessary for the work. The integration plan must provide a detailed explanation of the substantive research processes that will be integrated.5. IMPLEMENTATIONProvide a strategy for implementation. Projects must demonstrate solid scientific rationale, and applications must include published and/or preliminary data that support the feasibility of their hypotheses and/or approaches. The application must include a detailed research management plan that identifies critical milestones, outlines the innovations and technical solutions that will be implemented to accomplish the milestones, and explains how these solutions will ultimately be translated to individuals with, and/or at risk for, breast cancer. It is expected that the proposed plan will present an exceptional level of innovation and creativity.Accelerate research progress through communication. Communication between and among consortium team members is essential to the success of the consortium. Applications must include a strategy for sharing data in real time and using information technologies to facilitate timely and effective communication and cooperation. The communication plan should specify the processes and tools to be used for regular and structured communication. The consortium should take full advantage of state-of-the-art communication and data sharing tools in addition to formal and informal meetings. The framework for the communication plan must be part of the application and the individual(s) who will maintain the data sharing and communications technologies must be identified.Provide an effective, coordinated administrative management plan that integrates and optimizes the research and collaborations. The Consortium Director is required to commit a minimum level of time and effort of 25% to direct and manage an initiative of this magnitude, as well as lead their own project team. The Consortium Director must have the scientific ability and proven administrative ability to oversee large research programs and a proven record of leadership, including experience in the effective use of communication tools and the management of multifaceted and multidisciplinary projects. The administrative management plan must explain how the consortium will be organized and managed, and specify the processes and tools to be used for project meeting scheduling, reviews of research findings, ensuring multidisciplinary authorship of all publications arising from the consortiums work, and other issues of common concern to the consortium and its investigators. The administrative management plan also must describe procedures and processes that will be used to maximize the resources (e.g., databases, animal models) and products (e.g., antibodies) generated by the consortium and how these resources and products will be made available to the scientific community. A portion of the total direct budget costs must be reserved for a program manager.Award Structure: The Transformative Breast Cancer Consortium Award is structured to accommodate up to five PIs (the Consortium Director and three or four Project Team PIs). The Consortium Director will be responsible for the majority of the administrative tasks associated with application submission and the day-to-day management of the consortium. In addition, the Consortium Director will be responsible for leading their own project team. The Consortium Director and Project Team PIs each have different submission requirements; however, all PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named on separate awards to the recipient organizations. For individual submission requirements for the Consortium Director and Project Team PIs, refer to Section II.D.2, Content and Form of the Application Submission.The Consortium Director, Project Team PIs, and consumer advocates will be required to present an update on progress toward accomplishing research milestones and goals of the consortium and each project at an annual In-Progress Review (IPR) Meeting for the Transformative Breast Cancer Consortium Award. The intent of the IPR Meeting is to assess research progress, address problems, and define future directions. Annual IPR Meetings will be held at the conclusion of year 1 and every subsequent year in the period of performance and will be attended by members of the BCRP Programmatic Panel, CDMRP staff, and the USAMRAA Grants Officer to facilitate oversight and provide feedback to the consortium. IPR Meetings will either be held in person in the National Capital Region or virtually, at the discretion of the government. Continued funding may be contingent upon the successful completion of specific research milestones and goals. Research milestones from the approved SOW will be determined during the award negotiation process.In addition to IPR Meetings, each consortium must hold biannual workshops, which may be held at the PIs institutions or virtually, to facilitate ongoing communication and exchange of information within the consortium, as well as with advisory board(s) and/or steering committee(s).

This grant provides funding for innovative research and development of advanced quantum computing systems that integrate various architectural approaches to significantly improve performance, targeting a wide range of organizations including universities, businesses, and research centers.

This funding opportunity supports the establishment of a center to coordinate research on cellular senescence, aiming to improve health outcomes by identifying tissue-specific markers and developing new therapeutic strategies, targeting a wide range of eligible applicants including educational institutions, nonprofits, and businesses.

This funding opportunity provides financial support to U.S.-based organizations, including universities, nonprofits, and businesses, to help outsourcing facilities produce critical medications that are in short supply and vulnerable to fraud.

The Ports for the Future Partnerships grant, managed by the Bureau of Counterterrorism under the U.S. Department of State, is a discretionary funding opportunity designed to support initiatives in the transportation sector, specifically targeting port infrastructure development. This program will coordinate with the Quad (Australia, India, Japan, and the United States) to hold the first Quad Ports and Transportation Conference in Mumbai, India, in 2025. The grant's objective is to partner with organizations that have substantial experience and established networks in port infrastructure and management within the region. A primary focus will be on coordinating technical assistance and capacity-building efforts that meet the extensive infrastructure needs of regional ports, aligning with the strategic priorities of the Quad countries. The grant will be awarded as a cooperative agreement, enabling a close collaboration between the U.S. Department of State and the recipient to ensure the alignment of program activities with the initiative's strategic objectives. The total funding available for this award is $1,275,904, which also serves as both the maximum and minimum funding level for this grant, meaning only one award is anticipated. The program does not require cost-sharing or matching funds from the awardee, allowing for full coverage of approved project costs by the grant. Eligible applicants include a wide range of entities such as U.S.-based and foreign nonprofit and nongovernmental organizations (with or without 501(c)(3) status), for-profit organizations, public and private educational institutions, public international organizations, and governmental institutions. This broad eligibility requirement ensures that organizations with relevant expertise in port management, transportation, and infrastructure, regardless of their legal structure or location, can apply if they meet the program's criteria and objectives. Applicants interested in this opportunity must submit their applications by December 6, 2024. The application materials will likely need to include detailed descriptions of proposed activities, expertise in the sector, and strategies for aligning efforts with Quad priorities. While the full application requirements are not detailed here, interested applicants are encouraged to consult the full announcement on MyGrants for specific application guidelines. Evaluation criteria may involve the applicant's experience, access to networks in the region's ports sector, and their proposed approach to capacity-building and technical assistance coordination. Successful applicants will need to demonstrate their ability to contribute to the infrastructure goals of the Quad partnership and effectively engage with international partners to maximize the program's impact. For additional questions or difficulties accessing the application materials, applicants are advised to contact the grant officer at khanz@state.gov. This opportunity represents a chance to play a pivotal role in advancing infrastructure efforts in South and Central Asia in alignment with the shared security and economic goals of the Quad nations.

This funding opportunity supports early-stage researchers in the U.S. who are developing innovative projects to address the intersection of substance use disorders and HIV, with the goal of improving treatment and reducing incidence in affected populations.

This funding opportunity provides financial support for research and development of bus safety and accessibility improvements, targeting transit agencies, government entities, nonprofits, and private companies involved in public transportation.

Program Description Overview The U.S. Department of Justice (DOJ), Office of Justice Programs (OJP), the Office for Victims of Crime (OVC) is seeking applications for funding. OJP is committed to advancing work that promotes civil rights and equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety, protects the public from crime and evolving threats, and builds trust between law enforcement and the community. With this solicitation, OVC seeks to provide training and technical assistance to victim service providers supporting victims of all forms of human trafficking throughout the United States. This program furthers the DOJ’s mission to uphold the rule of law, to keep our country safe, and to protect civil rights.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for organizations interested in submitting applications for a project that strengthens the resilience of independent media and advances the protection and inclusion of marginalized populations in Lebanon.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

This grant provides funding for postdoctoral researchers from diverse backgrounds to receive training in translational research focused on Alzheimer's Disease and related dementias, enhancing their skills in interdisciplinary science and addressing health disparities.

This grant provides funding to small businesses to accelerate the development of advanced catalytic technologies that support the transition to sustainable energy and reduce carbon emissions.

The FY24 PRARP TrRA is intended to support studies that will make transformative and advanced contributions to reduce risk of or prevent the development of AD/ADRD. Risk reduction considering TBI and/or military service is of particular interest to the program. The work should significantly accelerate efforts in AD/ADRD research and demonstrate significant impact toward improving patient care and/or quality of life. To meet the intent of the funding opportunity, applications must robustly address an important problem or a critical barrier to progress in prevention and risk reduction. The proposed research may include, but is not limited to, exploring questions in the following areas: Identification of risk factors (environmental, genetic, epigenetic, lifestyle, etc.). Identification and implementation of strategies to reduce AD/ADRD risk and prevent cognitive problems following TBI and/or military service. Understanding the role of social determinants of health in risk reduction. Informational (not descriptive) epidemiology to understand environmental and other factors that contribute to development of AD/ADRD. All applications submitted to this funding opportunity must clearly indicate how the project addresses a critical unmet need, explain how the research will be representative of the population it intends to benefit, and demonstrate cultural competence. Culturally competent research factors the cultural background and diversity of the intended beneficiaries of the research outcomes when developing research ideas, conducting research, and implementing the research findings. Cultural competency in research is critical in reducing health disparities and enhancing the quality and impact of research by ensuring inclusivity, understanding, and responsiveness to the needs of diverse populations. Key elements of this award mechanism include: Research should be robust: The FY24 PRARP TrRA mechanism is geared toward supporting robust, well-designed research projects that provide significant impact on the AD/ADRD field, persons living with dementia, and their families, care-partners/caregivers. Inclusion of collaborative Community partner approaches is strongly encouraged for all projects and is required for all projects involving clinical research. Use of animal models must be fully justified for relevance to human health. Non-incremental advancement: Research projects should leverage existing knowledge to accelerate ideas, strengthen evidence, and move the field forward. Therefore, preliminary data are required. Projects proposing incremental advances that do not significantly propel the field do not meet the intent of this mechanism. Feedback to the Community: Applicants are expected to articulate a plan for relaying the results and outcomes of the research supported by this mechanism must be relayed back to the research/Community(ies) to allow for continued knowledge building. Optimizing research impact through Community collaboration: Research funded by the FY24 PRARP should be responsive to the needs of people living with AD/ADRD. Community collaboration is required for clinical research projects and encouraged for preclinical studies. Establishment and utilization of effective and equitable collaborations and partnerships with members of the AD/ADRD lived experience, family, and care partner communities, which will be referred to as Community(ies) in the remainder of the Funding Opportunity, maximizes the translational and impact potential of the proposed research. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of Community members within the research team. Collaborative research approaches such as Community-based participatory research, participatory action research, and integrated knowledge transition generate partnerships between scientific researchers and Community members to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and Community members must collaborate and contribute their expertise equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Research results are jointly interpreted, disseminated, fed back to affected communities, and may be translated into interventions or policy. These methods are critically important for Community-level interventions and can also augment the potential impact of a research program on people living with dementia, their families, and/or their care partners. These collaborative relationships are often established through integrating Community members into research teams as co-researchers, advisors, and consultants. Some examples for Community collaborations include: Lived Experience Consultation: The research team includes at least one project advisor with AD/ADRD experience who will integrate with the research team to provide consultation throughout the planning, implementation, and dissemination of the research project. Lived experience consultants (LECs) may include individuals with AD/ADRD, their family members, care partners, or others as appropriate. Partnership with a Community-Based Organization: The research team establishes partnerships with at least one Community-based organization that provides consultation throughout the planning, implementation, and dissemination of the research project. Community-based organizations may include advocacy groups, service providers, policymakers, or other formal organizational stakeholders. Community Advisory Board (CAB) Utilization: A CAB is composed of multiple Community stakeholders and can take many forms, from a board of LECs to a coalition of Community-based organizations or any combination thereof. As with LECs and organizational partners, the CAB provides consultation throughout the planning, implementation, and dissemination of the research project. Career Initiation or Transition (CIT) Partnership Option: The FY24 PRARP encourages applications that include meaningful and productive collaborations between two principal investigators. To promote enhanced research capacity within the AD/ADRD field, the FY24 TrRA includes an option for a CIT Principal Investigator (PI) to partner with an experienced to jointly address a research question. The CIT PI must have nominal, if any, research support in the field and may be either one of the following: The Career Initiation PI must be an early-career researcher, at least 3 years post their terminal degree but no more than 7 years into their independent position. Both PIs may have similar or disparate expertise, but each PI is expected to bring distinct and complimentary contributions to the application. The Career Transition PI must be an investigator (at any stage) who is new to the military health, TBI, or AD/ADRD field(s). New to the field is defined as having only nominal, if any, publications in the field. The other partnering investigator must have complimentary experience (as evidenced by publications) in military health, TBI, and/or AD/ADRD field(s). The CIT is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for most of the administrative tasks associated with application submission. The other will be identified as a Partnering PI. Either PI can be the CIT PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. Both PIs may have experience in similar or disparate scientific disciplines, but each PI is expected to bring distinct and complimentary contributions to the application. If recommended for funding, each PI will be named to an individual award within the recipient organization(s). For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

This program provides funding to small shipyards in the U.S. for capital improvements and workforce training to enhance their operational efficiency and competitiveness in shipbuilding and repair.

This program provides funding for research institutions and organizations to develop advanced techniques for improving the performance and reliability of quantum computing systems, specifically targeting applications in national defense.

The National Science Foundation's Directorates for Engineering (ENG), Computer and Information Science and Engineering (CISE), Mathematical Physical Sciences (MPS), and Social, Behavioral and Economic Sciences (SBE) are coordinating efforts to create fundamental understanding that will enablecontinued effective use of an essential common resource, the electromagnetic spectrum. Existing approaches to spectrum management and regulationhave struggled with the ever-increasing demands for spectrum created by continual emergence of new scientific, military, and commercial applications, powered by steady advances in wireless technologies. Development of fundamentally new models and paradigms of spectrum access and management, along with enabling technologies, is needed before it becomes too costly to accommodate new innovations and essential services, or too late to sustain the digital transformation and growth of key industries and public services. This program seeks to develop the intellectual capital enabling the U.S. to smoothly and quickly transition to effective new ways of using and managing the radio and optical spectrum after the end of the current spectrum era of long-term exclusive-use license auctions, thereby sustaining and advancing the social, economic, scientific, and U.S. national leadership benefits derived from the electromagnetic spectrum.

This grant provides funding to strengthen the capacity of the Ministry of Health in Eswatini to effectively respond to HIV, TB, and related public health challenges through technical assistance and the development of sustainable health strategies.

The FY24 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Research applications only in the area of mesothelioma will not be accepted. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY24 LCRP Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent). The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PIs expertise to best address the research question. All applicants for the New Investigator category must meet specific eligibility criteria as described in Section II.C, Eligibility Information.Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.Key elements of this award are as follows:Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating deaths and suffering from lung cancer.It is the responsibility of the PI to clearly and explicitly articulate the projects innovation and its potential impact on lung cancer and its relevance to Military Health System (MHS) beneficiaries. The projects impact to both lung cancer research and to patients with lung cancer should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the Idea Development Award.

The NIDCD Early Career Research (ECR) Award (R21) supports early-career scientists in conducting basic and clinical research related to hearing, balance, smell, taste, voice, speech, or language, with the goal of generating preliminary data for future R01 grant applications.

Notice of Funding Opportunity SummaryThe Natural Resources Conservation Service (NRCS), an agency under the United States Department of Agriculture (USDA) is announcing potential availability of cooperative agreements for the purpose of leveraging NRCS resources to assist our agency with conducting and implementing important conservation whole farm planning on multiple private landowner properties throughout Southeastern Massachusetts. NRCS recognizes the importance of expanding conservation efforts including irrigation, erosion control, integrated pest management, nutrient management and forestry efforts in Southeastern Massachusetts and the beneficial outcomes it can have on the environment. The agreement holder will also be responsible for providing training to NRCS staff and affiliates as well as customer outreach.NRCS-Massachusetts is making a funding opportunity available for applicants to submit proposals with an award ceiling of $400,000 and a minimum project award of $200,000. NRCS will be awarding a cooperative agreement for up to a five-year period. If, in coordination with NRCS, additional resources are needed at a rate that exceeds this schedule, NRCS may add funds to this agreement to support continued partnership over the performance period.The primary goal is to expand conservation planning to NRCS customers throughout Southeastern Massachusetts. The project list ranges in size from less than 1-acre farms to several hundred-acre farms. Applicants will identify the average number of conservation site visits and written whole farm conservation plans that they could complete in any year with a minimum of fifteen per year being acceptable for this agreement. NRCS will work with the selected applicant to make the choice of priority conservation site visits each year of the agreement based on interest and need. Applicants will be required to hold 1-2 conservation focused trainings per year for NRCS staff and partners to expand their technical knowledge. Applicants should provide a list of training ideas to NRCS for the length of the agreement. Applicants will be awarded based on the specified scoring criteria in Section E of this announcement. Eligible applicants include: all domestic applicants. Neither foreign entities nor individuals are eligible to apply for this opportunity. Applicants should be familiar with all applicable state, federal, local laws, policies, and regulations that apply to conservation improvements in the locales of Massachusetts.For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov.Key DatesApplicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on June 29, 2024. For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts.For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility, or the merits of a specific proposal will not be addressed.The agency anticipates making selections by June 30, 2024, and expects to execute awards by August 15, 2024. These dates are estimates and are subject to change.